71 evolution-"https:"-"https:"-"https:"-"https:"-"https:"-"Leiden-University" positions at City of Hope
Sort by
Refine Your Search
-
Listed
-
Category
-
Field
-
immunotherapy through engineered CAR T and/or CAR NK cells, oncolytic virotherapy, antibody development, stem cell (including iPSCs) research, depending on the individual’s interests and strengths. Under general
-
career development. For more information about Dr. You’s lab, please visit here. As a successful candidate, you will: Lead independent and collaborative projects investigating the molecular and cellular
-
that is ranked top 5 in the nation for cancer care by U.S. News & World Report at its core, City of Hope’s uniquely integrated model spans cancer care, research and development, academics and training, and
-
Clinical Trials (SCT) Operations Program Manager will support the development and implementation of strategic initiatives within Clinical Trial Operations. The Operations Manager will be responsible
-
visit here . If you are passionate about some of the following things, we are working on this may be the perfect opportunity: · Development of cell-free DNA (mutation and methylation), RNA, and
-
, shaping the future of medicine through cutting-edge research. We are looking for a Scientific Writer / Project Development Scientist who will be responsible for project management, scientific writing, and
-
: · Contribute to the development of CD38 antibody‑drug conjugates (ADCs) and other multiple myeloma targets, including monoclonal antibody (mAb) engineering, ADC conjugation, biophysical characterization (SPR
-
translated landmark scientific discoveries into treatments that have improved the lives of diabetic patients around the world. TRCT focuses on stem cell biology and development, translational and clinical
-
Cytometry Core Director to lead a high-performance shared resource supporting basic, translational, and clinical cancer research. The Director manages daily operations, technology development, and scientific
-
genes related to the development of type 2 diabetes and cardiovascular disease in the Hispanic population. He also continues to oversee the Diabetes and Cardiovascular Risk Reduction Program, which he